106 related articles for article (PubMed ID: 215719)
21. Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model. Antiviral and anti-inflammatory effects.
Takada H; Kishimoto C; Hiraoka Y
Circulation; 1995 Sep; 92(6):1604-11. PubMed ID: 7664447
[TBL] [Abstract][Full Text] [Related]
22. Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance.
Gebhard JR; Perry CM; Harkins S; Lane T; Mena I; Asensio VC; Campbell IL; Whitton JL
Am J Pathol; 1998 Aug; 153(2):417-28. PubMed ID: 9708802
[TBL] [Abstract][Full Text] [Related]
23. Coxsackievirus B3-induced myocarditis in MHC class II-deficient mice.
Leipner C; Borchers M; Merkle I; Stelzner A
J Hum Virol; 1999; 2(2):102-14. PubMed ID: 10225212
[TBL] [Abstract][Full Text] [Related]
24. Effect of myocrisin (sodium auro-thio-malate) on the morphogenesis of avirulent Semliki Forest virus in mouse brain: an electron microscopical study.
Pathak S; Webb HE
Neuropathol Appl Neurobiol; 1983; 9(4):313-27. PubMed ID: 6413876
[TBL] [Abstract][Full Text] [Related]
25. Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis.
Horwitz MS; La Cava A; Fine C; Rodriguez E; Ilic A; Sarvetnick N
Nat Med; 2000 Jun; 6(6):693-7. PubMed ID: 10835688
[TBL] [Abstract][Full Text] [Related]
26. Perinatal transmission of coxsackievirus B3 in mice.
Modlin JF; Bowman M
J Infect Dis; 1987 Jul; 156(1):21-5. PubMed ID: 3036959
[TBL] [Abstract][Full Text] [Related]
27. Coxsackievirus B4 infection of the mouse pancreas: the role of natural killer cells in the control of virus replication and resistance to infection.
Vella C; Festenstein H
J Gen Virol; 1992 Jun; 73 ( Pt 6)():1379-86. PubMed ID: 1607859
[TBL] [Abstract][Full Text] [Related]
28. Nitric oxide and murine coxsackievirus B3 myocarditis: aggravation of myocarditis by inhibition of nitric oxide synthase.
Hiraoka Y; Kishimoto C; Takada H; Nakamura M; Kurokawa M; Ochiai H; Shiraki K
J Am Coll Cardiol; 1996 Nov; 28(6):1610-5. PubMed ID: 8917278
[TBL] [Abstract][Full Text] [Related]
29. Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice.
Wolfgram LJ; Beisel KW; Herskowitz A; Rose NR
J Immunol; 1986 Mar; 136(5):1846-52. PubMed ID: 3005402
[TBL] [Abstract][Full Text] [Related]
30. Coxsackievirus B3 infection in human leukocytes and lymphoid cell lines.
Vuorinen T; Vainionpää R; Kettinen H; Hyypiä T
Blood; 1994 Aug; 84(3):823-9. PubMed ID: 8043865
[TBL] [Abstract][Full Text] [Related]
31. Systemic lymphoid atrophy in coxsackievirus B3-infected mice: effects of virus and immunopotentiating agents.
Matteucci D; Toniolo A; Conaldi PG; Basolo F; Gori Z; Bendinelli M
J Infect Dis; 1985 Jun; 151(6):1100-8. PubMed ID: 2987368
[TBL] [Abstract][Full Text] [Related]
32. Anti-mouse IgM immunoglobulin protects weanling mice from Coxsackievirus infection.
Heard HK; Jordan C; Stanton GJ
Microb Pathog; 1989 Dec; 7(6):399-409. PubMed ID: 2560114
[TBL] [Abstract][Full Text] [Related]
33. Colchicine aggravates coxsackievirus B3 infection in mice.
Smilde BJ; Woudstra L; Fong Hing G; Wouters D; Zeerleder S; Murk JL; van Ham M; Heymans S; Juffermans LJ; van Rossum AC; Niessen HW; Krijnen PA; Emmens RW
Int J Cardiol; 2016 Aug; 216():58-65. PubMed ID: 27140338
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of coxsackievirus B4 virulence by indomethacin.
Khatib R; Reyes MP; Smith F; Khatib G; Rezkalla S
J Lab Clin Med; 1990 Jul; 116(1):116-20. PubMed ID: 1695914
[TBL] [Abstract][Full Text] [Related]
35. Probable intrafamilial transmission of coxsackievirus b3 with vertical transmission, severe early-onset neonatal hepatitis, and prolonged viral RNA shedding.
Cheng LL; Ng PC; Chan PK; Wong HL; Cheng FW; Tang JW
Pediatrics; 2006 Sep; 118(3):e929-33. PubMed ID: 16908622
[TBL] [Abstract][Full Text] [Related]
36. Persistence of replicating coxsackievirus B3 in the athymic murine heart is associated with development of myocarditic lesions.
Sato S; Tsutsumi R; Burke A; Carlson G; Porro V; Seko Y; Okumura K; Kawana R; Virmani R
J Gen Virol; 1994 Nov; 75 ( Pt 11)():2911-24. PubMed ID: 7964602
[TBL] [Abstract][Full Text] [Related]
37. Alterations in coxsackievirus B4 heart muscle disease in ICR Swiss mice by anti-thymocyte serum.
Khatib R; Khatib G; Chason JL; Lerner AM
J Gen Virol; 1983 Jan; 64 (Pt 1)():231-6. PubMed ID: 6296300
[TBL] [Abstract][Full Text] [Related]
38. Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.
Lan J; Gao Z; Xiong H; Chuai X; Jin Y; Li J; Xian X; Liu G; Xie L; Zhang Y; Wang Y
Vaccine; 2011 Sep; 29(40):6894-902. PubMed ID: 21803097
[TBL] [Abstract][Full Text] [Related]
39. The role of B lymphocytes in coxsackievirus B3 infection.
Mena I; Perry CM; Harkins S; Rodriguez F; Gebhard J; Whitton JL
Am J Pathol; 1999 Oct; 155(4):1205-15. PubMed ID: 10514403
[TBL] [Abstract][Full Text] [Related]
40. Coxsackie B1 virus-induced murine myositis: relationship of disease severity to virus dose and antiviral antibody response.
Jongen PJ; Heessen FW; ter Laak HJ; Galama JM; Gabreëls FJ
Neuromuscul Disord; 1994 Jan; 4(1):17-23. PubMed ID: 8173348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
